Harvard Bioscience Inc.

149 articles with Harvard Bioscience Inc.

• Harvard Bioscience Announces New Credit Facility

  12/22/2020

  Harvard Bioscience, Inc. announced the refinancing of its debt with the closing of a new $65 million credit facility.

• Harvard Bioscience to attend Benchmark’s 9th Annual Discovery One-on-One Conference

  11/16/2020

  Harvard Bioscience, Inc. (Nasdaq: HBIO), today announced that Jim Green, Chairman, President and CEO, and Michael Rossi, CFO will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference.

• Harvard Bioscience Announces Third Quarter 2020 Financial ResultsDisciplined cost management, cash conservation actions drive increased year-over-year operating income and reduced net debt

  11/5/2020

  Operating margin up year-over-year on GAAP and adjusted basis Revenue improved sequentially with solid CRO/pharma demand and academic labs reopening Generated positive operating cash flow in Q3 with working capital improvements

• Harvard Bioscience Schedules Third Quarter 2020 Earnings Conference Call for November 5, 2020 at 8:00 AM ET

  10/20/2020

  Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for third quarter ended September 30, 2020 before the market opens on November 5, 2020, and will hold a conference call to discuss the results on November 5, 2020 at 8:00 a.m. Eastern Time.

• Harvard Bioscience to Present at Singular Research Compelling Values Webinar

  9/16/2020

  Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, President and CEO, will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020 at 2:15  p.m. ET. The presentation will be available online via a webinar. To listen to the live webcast, please register with Singular Research at https://www.singularresearch.com/index.php/en/ A slide presentation that will be referenced during the webcast

• Harvard Bioscience Announces Second Quarter 2020 Financial Results

  8/5/2020

  Accelerated cost reduction, cash conservation actions drive increased operating income, reduced net debt

• Harvard Bioscience Schedules Second Quarter 2020 Earnings Conference Call for August 5, 2020 at 8:00 AM ET

  7/20/2020

  Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for second quarter ended June 30, 2020 before the market opens on August 5, 2020, and will hold a conference call to discuss the results on August 5, 2020 at 8:00 a.m. Eastern Time. You can access the live conference call by dialing the following phone numbers: toll-free 1 (877) 303-7611 or international 1 (970) 315-0445 and referencing the conference ID # 4458189.

• Harvard Bioscience Announces First Quarter 2020 Financial ResultsImplemented significant cost reductions to offset Covid-19 impact on operating income

  5/5/2020

  Harvard Bioscience, Inc. announced financial results for the three months ended March 31, 2020.

• Harvard Bioscience Schedules First Quarter 2020 Earnings Conference Call for May 5, 2020 at 8:00 AM ET

  4/23/2020

  Harvard Bioscience, Inc. will announce its financial results for first quarter ended March 31, 2020 before the market opens on May 5, 2020, and will hold a conference call to discuss the results on May 5, 2020 at 8:00 a.m. Eastern Time.

• Harvard Bioscience Announces Appointment of Susan Steele to Board of Directors

  4/6/2020

  Engine Capital Withdraws Director Nomination Notice For 2020 Annual Meeting of Stockholders

• Harvard Bioscience Introduces Next Generation Inhalation System to Aid in the Fight Against COVID-19Company will continue to manufacture and ship innovative products for global development and research throughout crisis

  3/23/2020

  Harvard Bioscience, Inc. (Nasdaq: HBIO) has launched an innovative technology – known as Accumulated Inhaled Aerosol (AIA) –  for academic researchers, contract research organizations (CROs) and pharmaceutical companies involved in pre-clinical inhalation and exposure studies. With our new Buxco® AIA system, researchers are presented with real-time aerosol amounts inhaled and deposited in subjects’ lungs, a breakthrough improvement over the

• Harvard Bioscience Announces Fourth Quarter 2019 Financial ResultsSubstantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets

  2/26/2020

  HOLLISTON, Mass., Feb. 26, 2020 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) (the “Company”) today announced financial results for the three and twelve months ended December 31, 2019.   4 th Quarter 2019 FY 2019 Revenue $31.0 million $116.2 million Operating Income (GAAP) $1.6 million $0.4 million Adjusted Operating Income / Margin $5.6 million, 18.1% $14.9 million, 12.8% Diluted EPS (GAAP) $0.01 $(0.12) Adjusted Diluted EPS $0.08 $0.18  Ji

• CORRECTION – Harvard Bioscience Announces Fourth Quarter 2019 Financial ResultsSubstantially improves adjusted operating margins while taking actions to underpin 2020 profit and growth targets

  2/26/2020

  In a release issued under the same headline issued earlier by Harvard Bioscience, Inc., please note that the table titled "Consolidated Statements of Operations" had incorrect data in the first data column.

• Harvard Bioscience Schedules Fourth Quarter 2019 Earnings Conference Call for February 26, 2020 at 8:00 AM ET

  2/11/2020

  Harvard Bioscience, Inc. will announce its financial results for fourth quarter ended December 31, 2019 before the market opens on February 26, 2020, and will hold a conference call to discuss the results on February 26, 2020 at 8:00 a.m. Eastern Time.

• Harvard Bioscience to attend Benchmark’s 8th Annual Discovery One-on-One Conference

  11/21/2019

  The Benchmark Company’s 8th Annual Discovery One-on-One Conference to be held on December 4, 2019 at the New York Athletic Club.

• Harvard Bioscience Announces Third Quarter 2019 Financial Results

  11/5/2019

  Harvard Bioscience, Inc., announced financial results for the three and nine months ended September 30, 2019.

• Harvard Bioscience Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  11/1/2019

  Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that in connection with Yash Singh being named Executive Vice President, Cellular & Molecular Technologies on October 31, 2019,

• Harvard Bioscience Announces Executive Appointment - Yash Singh as Executive Vice President

  10/31/2019

  Harvard Bioscience, Inc. announced today that Yash Singh has been named Executive Vice President, Cellular & Molecular Technologies, reporting to Chairman, President and CEO, Jim Green..

• Harvard Bioscience Schedules Third Quarter 2019 Earnings Conference Call for November 5 at 4:30 PM ET

  10/22/2019

  Harvard Bioscience, Inc. will announce its quarterly results for third quarter ended September 30, 2019 after market close on November 5, 2019 and hold a conference call to discuss the results for the third quarter on November 5, 2019 at 4:30 p.m.

• Harvard Bioscience Announces Executive Appointment

  10/21/2019

  Harvard Bioscience, Inc. (Nasdaq: HBIO) announced today that Ken Olson has been named Vice President and General Manager, Pre-Clinical Systems (DSI), reporting to Chairman, President and CEO, Jim Green.